DK1259513T3 - Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling - Google Patents

Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling

Info

Publication number
DK1259513T3
DK1259513T3 DK01906554T DK01906554T DK1259513T3 DK 1259513 T3 DK1259513 T3 DK 1259513T3 DK 01906554 T DK01906554 T DK 01906554T DK 01906554 T DK01906554 T DK 01906554T DK 1259513 T3 DK1259513 T3 DK 1259513T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
DK01906554T
Other languages
Danish (da)
English (en)
Inventor
Susan Marie Reutzel-Edens
Erik Christopher Chelius
Sharon Van Den Berghe Snorek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1259513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1259513T3 publication Critical patent/DK1259513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DK01906554T 2000-02-25 2001-02-12 Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling DK1259513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (fr) 2000-02-25 2001-02-12 Nouvelle forme cristalline de n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-acide glutamique et procede correspondant

Publications (1)

Publication Number Publication Date
DK1259513T3 true DK1259513T3 (da) 2004-01-12

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01906554T DK1259513T3 (da) 2000-02-25 2001-02-12 Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling

Country Status (36)

Country Link
US (1) US7138521B2 (fr)
EP (1) EP1259513B1 (fr)
JP (1) JP4846158B2 (fr)
KR (1) KR100744917B1 (fr)
CN (1) CN1183135C (fr)
AR (1) AR029471A1 (fr)
AT (1) ATE249462T1 (fr)
AU (1) AU777047B2 (fr)
BR (1) BR0108604A (fr)
CA (1) CA2400155C (fr)
CO (1) CO5261585A1 (fr)
CZ (1) CZ303772B6 (fr)
DE (1) DE60100750T2 (fr)
DK (1) DK1259513T3 (fr)
DZ (1) DZ3283A1 (fr)
EA (1) EA004684B1 (fr)
EG (1) EG24073A (fr)
ES (1) ES2206403T3 (fr)
HK (1) HK1051856A1 (fr)
HR (1) HRP20020701B1 (fr)
HU (1) HU229704B1 (fr)
IL (2) IL150480A0 (fr)
MX (1) MXPA02008242A (fr)
MY (1) MY124784A (fr)
NO (1) NO323422B1 (fr)
NZ (1) NZ519796A (fr)
PE (1) PE20011082A1 (fr)
PL (1) PL208061B1 (fr)
PT (1) PT1259513E (fr)
SI (1) SI1259513T1 (fr)
SK (1) SK287375B6 (fr)
SV (1) SV2002000321A (fr)
TW (1) TWI237024B (fr)
UA (1) UA72791C2 (fr)
WO (1) WO2001062760A2 (fr)
ZA (1) ZA200205265B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
CA2636596A1 (fr) * 2005-11-04 2007-05-18 James Pluda Traitement anticancereux au saha et au pemetrexed
EP1942907A2 (fr) * 2005-11-04 2008-07-16 Merck and Co., Inc. Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer
US7994180B2 (en) * 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
EP2305681A1 (fr) * 2006-08-14 2011-04-06 Sicor, Inc. Forme cristalline de diacide de pemetrexed et son procédé de préparation
JP2008543975A (ja) 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
JP2010509221A (ja) * 2006-11-03 2010-03-25 ユニバーシテイ・オブ・メリーランド，ボルテイモア 多発性骨髄腫を治療するためにｓａｈａおよびボルテゾミブを使用する方法
JP2010523589A (ja) * 2007-04-03 2010-07-15 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドの固体形
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010028105A2 (fr) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Disodium de pemetrexed amorphe
WO2010030598A2 (fr) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques comprenant du pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
ES2639639T3 (es) 2011-03-25 2017-10-27 Scinopharm Taiwan, Ltd. Proceso para la producción de pemetrexed disódico
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (fr) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Procédé de préparation de dipotassium de pemetrexed cristallin
US20150359898A1 (en) 2013-02-06 2015-12-17 Cipla Limited Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes
EP2983649A1 (fr) 2013-04-12 2016-02-17 Actavis Group PCT ehf Formulation de pemetrexed
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
JP2016527227A (ja) 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
EP3040074B1 (fr) 2013-10-03 2018-07-25 Fujifilm Corporation Préparation pharmaceutique d'injection, et procédé de fabrication de celle-ci
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA3015436C (fr) 2014-10-30 2020-07-21 Scinopharm Taiwan, Ltd. Formes cristallines de diacide de pemetrexed et procedes de fabrication connexes
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
AU2018349426B2 (en) * 2017-10-10 2024-01-18 Sun Pharmaceutical Industries Limited Intravenous infusion dosage form for pemetrexed

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
WO1998008382A1 (fr) * 1996-08-30 1998-03-05 Eli Lilly And Company Antifoliques non classiques de pyrrolo[2,3-d]pyrimidine
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
UA53742C2 (uk) * 1997-09-26 2003-02-17 Елі Ліллі Енд Компані Спосіб одержання альдегідів, які використовують при синтезі сполук, цінних як антифолати
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
NZ519796A (en) 2003-01-31
NO20023974D0 (no) 2002-08-21
UA72791C2 (uk) 2005-04-15
TWI237024B (en) 2005-08-01
SK11862002A3 (sk) 2003-01-09
AR029471A1 (es) 2003-07-02
US20030216416A1 (en) 2003-11-20
WO2001062760A3 (fr) 2001-12-06
DE60100750T2 (de) 2004-07-29
JP4846158B2 (ja) 2011-12-28
NO20023974L (no) 2002-08-21
CN1183135C (zh) 2005-01-05
CA2400155A1 (fr) 2001-08-30
EG24073A (en) 2008-05-11
SI1259513T1 (en) 2003-12-31
HUP0204232A3 (en) 2006-01-30
MY124784A (en) 2006-07-31
PE20011082A1 (es) 2001-10-22
EA200200905A1 (ru) 2003-02-27
HU229704B1 (en) 2014-05-28
CZ20022875A3 (cs) 2003-02-12
SK287375B6 (sk) 2010-08-09
HRP20020701A2 (en) 2003-12-31
EP1259513A2 (fr) 2002-11-27
ES2206403T3 (es) 2004-05-16
HRP20020701B1 (en) 2011-02-28
AU777047B2 (en) 2004-09-30
US7138521B2 (en) 2006-11-21
KR20020075449A (ko) 2002-10-04
ATE249462T1 (de) 2003-09-15
DE60100750D1 (de) 2003-10-16
WO2001062760A2 (fr) 2001-08-30
NO323422B1 (no) 2007-04-30
SV2002000321A (es) 2002-07-16
EA004684B1 (ru) 2004-06-24
ZA200205265B (en) 2003-11-11
EP1259513B1 (fr) 2003-09-10
AU3445101A (en) 2001-09-03
BR0108604A (pt) 2002-11-19
PT1259513E (pt) 2004-02-27
DZ3283A1 (fr) 2001-08-30
IL150480A (en) 2007-12-03
PL356423A1 (en) 2004-06-28
JP2003530321A (ja) 2003-10-14
CN1406238A (zh) 2003-03-26
MXPA02008242A (es) 2002-11-29
IL150480A0 (en) 2002-12-01
HUP0204232A2 (hu) 2003-04-28
KR100744917B1 (ko) 2007-08-01
CA2400155C (fr) 2009-09-15
CZ303772B6 (cs) 2013-05-02
CO5261585A1 (es) 2003-03-31
PL208061B1 (pl) 2011-03-31
HK1051856A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
DK1259513T3 (da) Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling
NO20050524L (no) Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
EE200300594A (et) (1-bensüül-4-metüülpiperidiin-3-üül)metüülamiini optiline lahutamine ja selle kasutamine pürrolo-2,3-pürimidiini derivaatide kui proteiinikinaasi inhibiitorite valmistamiseks
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20044388L (no) Derivater av N-[fenyl(piperidin-2yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutika
NO20034751D0 (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
DK1513516T3 (da) Substitueret 3-amino-thieno(2,3-b)-pyridin-2-carboxylsyreamid-forbindelser og fremgangsmåder til fremstilling og deres anvendelser
DK1757606T3 (da) Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
DK1326853T3 (da) Nye thiadiazoler og oxadiazoler og deres anvendelse som inhibitorer af phosphodiesterase 7
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DK1330455T3 (da) Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
HUP0402129A3 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives, preparation thereof, compositions containing the same and processes for their use
EE200300435A (et) 4-(2-butüülamino)-2,7-dimetüül-8-(2-metüül-6-metoksüpürid-3-üül)[1,5-a]pürasolo-1, 3,5-triasiin, selle farmatseutiliselt vastuvõetavad eelravimid võifarmatseutiliselt vastuvõetavad soolad ning nendekasutamine
IL157061A (en) Process and intermediates for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl)piperazin -1-yl)-methanone and salts thereof
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
NO20015042D0 (no) Fremgangsmåter for fremstilling av optisk aktive aminosyrederivater
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
AU2003215677A1 (en) N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases
DK1153015T3 (da) Pyrimidin-2,4,6-trioner som inhibitorer af matrix-metalloproteinaser
DK1392650T3 (da) Beskyttede tyrosinderivater, fremgangsmåde til deres fremstilling og deres anvendelse til fremstilling af O-(2-[18F]-fluorethyl)-L-tyrosin